All articles tagged with #danaher
Originally Published 2 months ago — by Danaher Corporation Investors
Danaher reported strong Q3 2025 results with $908 million in net earnings, a 4.5% revenue increase to $6.1 billion, and an optimistic full-year outlook maintaining adjusted earnings guidance of $7.70-$7.80 per share, driven by growth in bioprocessing and respiratory segments.
Originally Published 2 years ago — by Danaher | Investor Overview
Danaher Corporation has announced an agreement to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at cost to the Global Fund to Fight AIDS, TB and Malaria and less-developed countries eligible for Cepheid's Global Access Program. By reducing the price of the test cartridge to $7.97, Danaher will earn no profit. The agreement expands the partnership between Cepheid and the Global Fund, aiming to improve access to high-quality TB testing in countries where it is most needed. The Global Fund is the largest provider of financing and programs to combat TB globally.
Originally Published 2 years ago — by Barron's
Danaher has announced its acquisition of biotech company Abcam in a $5.7 billion deal, which has received mixed reactions from investors due to the premium involved.
Originally Published 2 years ago — by Danaher | Investor Overview
Danaher Corporation has announced its plans to acquire Abcam plc, a global supplier of protein consumables, for $5.7 billion. Abcam will operate as a standalone company within Danaher's Life Sciences segment, aligning with Danaher's strategy to advance drug discovery and diagnostics. The acquisition is expected to close in mid-2024, subject to regulatory approvals and shareholder approval.
Originally Published 2 years ago — by CNBC
JPMorgan Chase has come to the rescue of First Republic in a deal that has implications for the U.S. banking system. Meanwhile, equity research firm recommends buying Danaher and owning Club stock for the long term.
Originally Published 2 years ago — by CNBC
Danaher, a life sciences and medical diagnostics company, reported a first-quarter earnings beat but lowered its outlook, causing a drop in its stock price. The revised guidance has prompted a reassessment of the investment case for Danaher, with its rating under review and price target lowered.